development of innovative treatments for pancreatic cancer

Silexion Therapeutics is a pioneering developmental stage
company Formerly known as Silenseed, the company has
developed its first-generation LODERTM product

Read About Us

We strive to develop novel therapies that can revolutionize cancer treatment, providing patients with new hope and improved outcomes

Silexion Company Profile

Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. 
The company conducted phase 2 clinical trial with its first generation product which has shown positive efficacy results vs the control of chemotherapy alone. 

Silexion’s commitment to pushing the boundaries of therapeutic advancements in the field of oncology, is focused in enhancing its first-generation product (LODERTM) to develop a new formulated product which will improve the clinical efficacy that Silexion observed with its first-generation product against pancreatic cancer.

Core Technologies

RNA Interference (RNAi)

With a strong foundation in RNA interference technology, Silexion Therapeutics develops innovative RNA-based therapeutics designed to silence specific genes involved in pancreatic cancer growth and metastasis. By selectively suppressing these genes, we aim to disrupt tumor progression and enhance the therapeutic response.

Targeted Drug Delivery

Silexion Therapeutics in collaboration with leading partner pioneer advanced drug delivery technologies that enable precise targeting and localized drug release within the tumor microenvironment. These technologies enhance the efficacy of therapeutic agents while minimizing off-target effects and reducing systemic toxicity.

Our vision is to establish treatment dedicated to addressing the complex and devastating impact of cancer on individuals and communities worldwide.

SIL-103- Silexion Product

Silexion Technology is a platform technology consisting of siRNA and PLG microparticle product for the treatment of solid tumors.

Why SIL 103?

  • Improve siRNA delivery by formulating into bioabsorbable PLG microparticles of about 30-70 µm that will simultaneously release two siRNAs for 2-3 months in the pancreatic tumor.
  • Add 2 siRNAs with a stronger inhibition profile towards G12V, and G12D, the most abundant mutants in Pancreatic Cancer.
  • SIL 103 is delivered directly into the tumor and can be spread throughout the tumor surface area due to its liquid emulsion formulation.

Silexion Therapeutics combines cutting-edge science, advanced technologies, and a passion for innovation to address the significant unmet medical needs in pancreatic cancer treatment.

Publications

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

Find Out More ⟶

Mutant Kras is a druggable target for pancreatic cancer

Find Out More ⟶

Multistep effective drug distribution within solid tumors

Find Out More ⟶

Contact Us

Mirit Horenshtein Hadar, CPA E.V.P Finance Affairs

Mirit brings over 15 years of multinational managerial and corporate finance experience as a CPA in senior financial positions of public companies traded on NASDAQ and privately held companies prior IPO phase, in pharmaceutical and high-tech industries, as well as in international auditing firm. Mirit has been instrumental in building the financial infrastructure of companies towards its next phase of growth, leading the accounting, financial reporting and FP&A functions; Mirit has full spectrum of accounting and extensive finance experience in financial reporting under US GAAP, in compliance with SEC regulations and PCAOB standards, both as foreign public issuer and domestic filer. She is highly experienced in auditing financial statements for both public multinational companies and privately held companies in Israel and aboard, as an external auditor in one of the Big 4 auditing firm in Israel.

Over her time in corporate senior finance positions, Mirit has been a strategic business partner to the CEO and senior executive leadership team, collaborate with the R&D, S&M, commercial, manufacturing, regulatory and QA executive teams, to support in decision making regarding company’s financial strategy and operations. Mirit successfully took part in complex M&A deals including reverse triangular mergers, leading the M&A accounting and related SEC reporting, and managing the integration processes of the acquired entities into the group, while leading the financial strategy and operations of the organization towards the next milestones ahead. During her last roles, Mirit has took a substantial role in companies fundraising plans and capital structure such as capital raising, public offerings and debt deal transactions, as well as managing investor relations and press releases, FP&A responsibilities such as budgeting, forecasting, financial modeling, cash management, product costing, hedging, SOX evaluation effectiveness of ICFR and risk management.

Currently, Mirit is serving as the E.V.P Finance Affairs of Silexion Therapeutics Ltd. Silexion is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. Prior to joining Silexion, Mirit served as CFO Israel of Gauzy Ltd., a nanotechnology company developing, manufacturing and commercializing Polymer Dispersed Liquid Crystal (PDLC) and Suspended Particle Device (SPD) films for lamination by glass fabricators and installation by window film installers, where she was successful in managing the financial activities of the company in Israel and its subsidiaries aboard and building the infrastructures for its next phase of growth. Prior to Gauzy, Mirit served as Senior Director of Finance, as Head of FP&A, Accounting and Financial Reporting at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE), where she took a leading role in several public offerings at Nasdaq and was instrumental in managing the company’s SEC filing process of timely consolidated financial statements, proxy statements and miscellaneous filings, oversee quarterly period-end closure process and ensure quality control over financial reporting and SOX controls effectiveness. Prior to Foamix, Mirit was a Senior Manager at PriceWaterhouseCooper (PwC Israel), as an external auditor, from 2008 to 2016. Mirit is a Qualified CPA since 2011 and received her BA degree in Accounting, Economics and Business Management B.A. at Tel Aviv University, Israel.

Orit Pollack–Shragai, M.Sc, MBA- VP Clinical Operations

Mrs. Pollack Shragai brings  over  two  decades  of relevant academic education, research and work experience in the biomed industry working for CRO, big pharma and start-up companies, managing local and international clinical trials (including mega trials) in drugs and medical devices. Prior to joining Silenseed, Mrs. Pollack Shragai served as Director of Clinical Operations and Active Advisor to several pharmaceutical companies 

Mrs. Pollack Shragai holds a  B.Sc  in  Food  Engineering  and  Biotechnology  from  the  Technion  in  Israel,  M.Sc  in Biotechnology  from  the  Hebrew  University  and  MBA  from  the  College  of  Management Academic Studies.

Michal Yaron- VP Regulatory Affairs

Mrs. Yaron holds 17 years of professional regulatory and product development experience across the pharmaceutical industry, with products from early stage through POC and regulatory approvals by multiple health authorities. Previously Mrs. Yaron held Regulatory Affairs managerial positions at Sol-Gel Technologies, Polypid, and Teva Pharmaceuticals Ltd. Mrs. Yaron Holds a M.Sc. degree in Chemistry.

Dr. Revital Maor Aloni

Dr. Revital Maor Aloni Joined Silenseed in December 2019 and led the quality of the KRAS-LODER from phase II. She also led the process for gaining a GMP approval from the Israeli Ministry of health for the LODER. Prior to joining Silenseed Dr. Maor Aloni has served as Director of Quality in SciVak Ltd. a biotechnology company from 2017, and prior to that as Director of Quality systems in Lumenis, a medical device company. Dr. Maor Aloni also served as senior manager in Aminolab Ltd. For 6 years as head of the Microbiology department and the chemistry department. Dr. Maor Aloni holds a Ph. D in microbiology from Ben-Gurion University in Beer-Sheva and Post-Doctorate from the Weizmann Institute of Science in Rehovot, Israel.

Dr. Racheli Malka Gabai

VP Pharmaceutical Development, Ph. D- Dr Gabai Malka Joined Silenseed in February 2009 and leads the development of the formulation and the production of the KRAS-LODER from the concept stage and up to Phase II. Dr Gabai Malka holds a B.Sc. in Chemistry and a M.Sc. in Chemistry both from the Hebrew University in Jerusalem and holds a Ph.D. and a Post-Doctorate in Chemistry from the Weizmann institute of science in Rehovot, Israel.

Dr Gabai Malka is a co-author of 12 scientific papers and co-inventor of 8 of the Silenseed’s granted patents.

Dr. Mitchell Shirvan

CSO, Ph.D. Prior to joining Silenseed Dr. Shirvan has served as the Senior Vice President of R&D and V.P. Innovation and Discovery at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since August 2017. Dr. Shirvan has been with Foamix since March 2014.  He has over 25 years of industry experience, previously holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held various positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior Manager, Research & Development. Prior to this he was a research fellow at the US National Institutes of Health.  Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem, and an MBA from the University of Bradford.

Ilan Hadar

Ilan brings over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies. Ilan has been instrumental in building companies from start-ups to hundreds of millions of dollars in operations. He successfully took part in the development, approval, and launch of new pharmaceutical products in the U.S. and Israel. Ilan has also been responsible for leading the operations, R&D, manufacturing, regulatory, and corporate finance for premier healthcare companies in the U.S. and Israel.

Currently, Ilan is serving as the CEO of Painreform Ltd. (“PRFX”) in addition to serving as Silexion’s Managing Director.  Painreform proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post-surgically. Prior to joining Painreform and Silexion, Ilan served as Country Manager Israel and CFO at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since 2014, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., as well as a focus on capital markets and M&A. Prior to Foamix, Ilan was Finance Director at Pfizer Pharmaceutical Ltd., where he oversaw all commercial, financial and operational activities of the local entity. Prior to that, Ilan served as Finance Manager at HP Indigo Ltd, a world-leading company in digital printing. Prior to that, Ilan was Finance Director at BAE Systems (FTSE:BA), the third-largest defence company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2006, Ilan was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions, where he was successful in building the company from the incubator stage to a multinational, multi-million dollar revenue-generating company. Ilan served on the Board of Directors at Kadimastem, a public Israeli biopharmaceutical company (TASE: KDST) from 2019 to 2022. Ilan received his MBA in Finance and Business Entrepreneurship and B.A. degree at The Hebrew University in Jerusalem, Israel.